Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: antisense oligonucleotides targeting COVID-2019 infections - Sarepta Therapeutics/United States Army Medical Research Institute of Infectious Diseases

Next Previous
Drug Profile

Research programme: antisense oligonucleotides targeting COVID-2019 infections - Sarepta Therapeutics/United States Army Medical Research Institute of Infectious Diseases

Alternative Names: Anti-SARS-CoV-2 antisense oligoneucliotides

Latest Information Update: 28 May 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sarepta Therapeutics
  • Developer Sarepta Therapeutics; United States Army Medical Research Institute of Infectious Diseases
  • Class Antisense oligonucleotides; Antivirals
  • Mechanism of Action Genetic transcription inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported COVID 2019 infections

Most Recent Events

  • 28 May 2024 No recent reports of development identified for research development in COVID-2019-infections in USA (Parenteral)
  • 28 Apr 2020 Sarepta Therapeutics establishes CRADA with United States Army Medical Research Institute of Infectious Diseases for the development of anti-SARS-CoV-2 antisense oligonucleotides in COVID-2019 infections
  • 28 Apr 2020 Early research in COVID-2019 infections in USA (Parenteral) before April 2020

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top